CSL Limited is a public company which is a parent company of the CSL Group. CSL business activities operate in the Human Health, JRH Biosciences, Animal Health and ZLB Plasma Services operations. CSL limited develops, manufactures and markets pharmaceutical products of biological origin. The company' s business is: - Health care; - Life-saving products derived from human plasma; - Pharmaceuticals and diagnostics essential to health; - Cell culture reagents for the pharmaceutical industry; - Veterinary vaccines and diagnostics to protect livestock and companion animals.

University Health Network (UHN) is a healthcare and medical research organization in Toronto, Ontario, Canada. It is the largest such research organization in Canada and North America, ranking first in Canada for total research funding. It was named Canada's top research hospital by Research Infosource in 2015, 2016 and 2017. It was created in 1986 by the Government of Ontario through the merger of four major hospitals: Toronto General Hospital, Toronto Western Hospital, with the Princess Margaret Cancer Centre, and the Toronto Rehabilitation Institute merged in with The Toronto Hospital in 1999 and the name changed to the University Health Network. All four hospitals are affiliated with the Faculty of Medicine at the University of Toronto and serve as teaching hospitals for resident physicians, nurses, and other healthcare professions. UHN also operates The Michener Institute, an applied health sciences college that opened in 1958.

Flash is developing an oral compound to prevent AML relapse using novel findings linking HCK to AML. This small molecule will inhibit HCK and FLT3-ITD for the treatment of cancer. They have identified five potential compounds for further testing. One is moving on to IND filing while the other four are going to begin animal toxicology testing.

Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

Riken Corp. engages in the manufacture and sale of engine and vehicular components. It operates through the Automotive and Machinery Parts, and Others segments. The Automotive and Machinery Parts segment deals with the company's core products such as piston rings, camshafts, seal rings for transmissions, high-grade cast iron products, and valve lifters. The Others segment includes plumbing equipment business, Electromagnetic Compatibility (EMC) business, and thermal engineering business, The company was founded by Masatoshi Okochi in November 1927 and is headquartered in Tokyo, Japan.

Celgene Corporation is an American biotechnology company that discovers, develops and commercializes medicines for cancer and inflammatory disorders. It is incorporated in Delaware and headquartered in Summit, New Jersey. The company's major product is Revlimid (lenalidomide), in combination with dexamethasone for the treatment of multiple myeloma patients. Revlimid is also approved in the United States for the treatment of patients with transfusion-dependent anemia, due to Low- or Intermediate-1-risk Myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. Revlimid is sold through proprietary risk-management distribution programs, to ensure safe and appropriate use of these pharmaceuticals. Vidaza is approved for the treatment of patients with MDS.

Yakult Honsha Co., Ltd. engages in the manufacture and sale of food and beverage products, cosmetics, and pharmaceuticals. It operates through the following segments: Food and Beverages in Japan, the Americas, Asia and Oceania, and Europe; Pharmaceuticals, and Others. The Food and Beverages segment produces and merchandises milk drinks, noodles, juices, and soft drinks. The Pharmaceuticals segment manufactures and sells anti-cancer drugs and other pharmaceutical products. The Others segment includes cosmetics and professional baseball team management. The company was founded by Minoru Shirota in 1935 and is headquartered in Tokyo, Japan.

Oxford University Innovation is the University of Oxford's technology transfer company and manages the University's intellectual property portfolio, working with University researchers on identifying, protecting and marketing technologies through licensing, spin-out company formation and material sales. Oxford University Innovation also manages Oxford University Consulting, which arranges consulting services providing clients access to the expertise of the University's academics. Oxford University’s overarching Strategic Plan begins, “The University of Oxford aims to lead the world in research and education” immediately followed by, “They seek to do this in ways which benefit society on a national and a global scale.” Oxford University Innovation helps staff and students to apply their expertise and research for wider social and economic benefit. Their role is to help University staff and students bring the benefits of their research and expertise to create impact in wider society. They support Oxford’s researchers, staff and students, offering commercial skills and a range of specialist resources in order to maximise research impact. Income is shared with those involved according to the University’s Regulations.

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

ChemGenex Pharmaceuticals, Inc. manufactures and develops pharmaceuticals. It develops novel protein, antibody, & small molecule therapeutics in the areas of oncology, obesity, diabetes, and central nervous system disorders. The company is a subsidiary of Chemgenex Pharmaceuticals Ltd. It was founded in 2004 and is headquartered in Menlo Park, CA.

Imperial Innovations is a technology commercialization and venture capital investor that focuses on technology. Imperial Innovations no longer invests in startups and now functions as the technology-transfer office of Imperial College. Imperial Innovations is focused on commercialising leading UK academic research sourced from the 'golden triangle' formed between Cambridge, Oxford and London. We are a technology commercialisation company that combines the activities of technology transfer, intellectual property protection and licensing, company incubation and investment. Innovations is focused on commercialising the most promising UK academic research across a broad range of technology sectors, and has developed particular expertise in: therapeutics, medtech, engineering and materials and information communication technology.

Argenx BV, a subsidiary of argenx SE, is a company headquartered in Belgium. The firm develops antibody ecosystems.

Hemei Biotechnology (Zhejiang) Co., Ltd., established on 2018-03-30, Business scope includes general items:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Medical Research and Experimental Development;R&D and application of cell technology;New material technology promotion service;software development;software sales;Cosmetics Retail;Cosmetics Wholesale;General merchandise sales;Home Appliance Sales;Sales of hygiene products and single-use medical products;Sales of Class I Medical Devices;Information Consulting Service(Not including licensing information consulting services);Advertising Design,acting;advertisement making;advertising;Technology Import and Export;Import and export;(animal)Umbilical Cord Extract,Oligopeptide,Production of polypeptide and hydrolyzed protein raw materials(The branch office is located in:Asia Pacific Industrial Park, Daqiao Town, Nanhu District, Jiaxing City, Zhejiang ProvinceA7building301,303room)(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license).licensed items:food sales(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results).

Centre Hospitalier Regional Universitaire de Lille is a private company headquartered in the United States. The firm operates hospital.

Institut Jean Paoli & Irene Calmettes is a non-profit organization engaging in fighting cancer. The company is headquartered in Marseille, France.

The Feinstein Institutes for Medical Research comprise the research arm of Northwell Health. Feinstein is home to 50 research labs, 2,500 clinical research studies, and 4,000 professional and support staff. Feinstein researchers have made breakthroughs in molecular medicine, genetics, cancer, brain research, mental health, autoimmunity and bioelectronic medicine, among others, and continue work in those and other areas. Feinstein is the laboratory and faculty home of the Elmezzi Graduate School of Molecular Medicine. Additionally, students without an MD degree may earn a PhD in molecular medicine via the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, as part of the medical school's MD/PhD or PhD programs.